Clearing the Smoke: Underreporting of Smoking Status in Food and Drug Administration-Approved Bladder Cancer Therapeutic Trials

J Urol. 2024 Apr;211(4):611-613. doi: 10.1097/JU.0000000000003853. Epub 2024 Feb 1.

Authors

Hannah Kay¹, Richard S Matulewicz², Marc A Bjurlin^{1

3}

Affiliations

¹ Department of Urology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
² Department of Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, New York, New York.
³ Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.

PMID: 38299550
DOI: 10.1097/JU.0000000000003853

No abstract available

Keywords: bladder cancer; clinical trial; drug; smoking; tobacco.

Publication types

Editorial

MeSH terms

Clinical Trials as Topic
Humans
Smoking* / epidemiology
United States / epidemiology
United States Food and Drug Administration
Urinary Bladder Neoplasms* / drug therapy
Urinary Bladder Neoplasms* / epidemiology